Among the infinite symposia, webinars, and white papers on this topic, “KOL identification” and “KOL mapping” can find themselves melting together in a gelatinous jargon
KOL identification and KOL mapping are often spoken about together, often treated as the same entity would simply a difference in terminology. They are however very different, yet synergistic.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh